Brazil’s Sao Paulo Butantan announced Tuesday that the CoronaVac coronavirus disease vaccine developed by China’s Kexing, according to the latest test results show that the effectiveness of only more than 50%, compared to the earlier test effectiveness of 78% fell almost 30 percentage points, only to meet the WHO standards, the New York Times described the test results of China’s attempts to achieve diplomatic purposes with the vaccine, the impact to huge. According to the report, at least 10 countries around the world have pre-ordered more than 380 million doses of the vaccine developed by Kexing.
Beijing Kexing Zhongwei Biotechnology Chairman Yin Weidong said at a press conference held on the mainland on the 13th that the results of the Phase III clinical tests conducted by Kexing vaccine in various places have proved that the safety and effectiveness of the vaccine is good around the world, and the Phase I production line with an annual production capacity of 500 million vaccines has been completed and put into production, and the Phase II production line is expected to be put into production next month, and it is expected that 1 million doses of the vaccine for Hong Kong will arrive on time according to the contract.
Wan said, divided into three phases of clinical testing from nearly 100% to 78% to the third phase of 50.3%, proving that the safety and effectiveness of the vaccine around the world is good.
The Kexing vaccine is one of three new crown vaccines pre-ordered in Hong Kong. For the latest test results of the Kexing vaccine compared to the last efficiency fell almost 30 percentage points, the Secretary for the Civil Service Nip Tak-kuen was asked whether the protection rate of the Kexing vaccine is not enough, he said the vaccine in Hong Kong before vaccination must be reviewed and examined by a committee of consultants and experts, based on clinical data and expert opinion for vaccination recommendations. Nip also pointed out that the vaccine is approved for emergency use by drug regulatory agencies outside Hong Kong, and the Hong Kong government will also give emergency use in accordance with the law, will ensure that the vaccine is safe and effective, and the quality of confidence before giving vaccination to the public.
As for another vaccine by Fosun and the German pharmaceutical company BioNTech will arrive in Hong Kong next month, Nie Dequan pointed out that Hong Kong will arrange vaccination in the Lunar New Year at the earliest, when the vaccination centers will be set up in all 18 districts in Hong Kong, the vaccination of the above vaccine requires a higher standard of treatment, as for the elderly homes will have outreach vaccination team responsible for the completion of the vaccination program, the government will account for the related expenses.
Hong Kong Hospital Pharmacists Association President Chui Chun-ming said that the overall efficiency of the Kexin vaccine is only 50.38%, because the elderly and immune system is not sound people with a lower immune response, may be vaccinated with the vaccine after the efficiency will be less than 50%, resulting in limited protection, it is recommended that the Government does not arrange for elderly people in residential care homes to receive the Kexin vaccine, should be replaced by the German BioNtech vaccine, the current data show that although the German Although the current data show that the side effect rate of the German BioNtech vaccine is higher than that of Coxing, but because of the lower immune response of the elderly, side effects are believed to be relatively reduced.
He also pointed out that although the efficiency of the Kexing vaccine, relative to the requirements of the WHO is just a pass, but he does not support the abandonment of Kexing, because the global supply of vaccines is tight, if abandoned Kexing may not have enough vaccine for the public to vaccinate, and Kexing vaccine can be left to young or healthy people who are willing to vaccinate, I believe it can produce 50% of the protective effect.
Respiratory specialist Dr. Leung Tze Chiu said that the data on the efficiency of the Kexing vaccine has dropped, I believe it is because this time the data includes The prevention of very mild symptoms after infection cases, pulling down the efficiency. The three vaccines ordered in Hong Kong are highly protective against moderate to severe symptoms after infection, establishing individual protection, but the three vaccines do not have comprehensive data to show that they can prevent infection without symptoms, that is, there may be vaccinees with no symptoms after infection, but still can spread the virus, affecting the herd immunity effect, so it is too early to say whether the vaccine can establish herd immunity in Hong Kong, but at least after vaccination can prevent moderate to severe However, at least the vaccination can prevent moderate to severe disease, reduce hospital admissions, and reduce the pressure on the medical system.
Recent Comments